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1. Introduction
The term oral cancer is used as a synonym for squamous cell carcinoma, which constitutes 90%
of malignant neoplasms. Surgery, radiotherapy and chemotherapy are the election treatments.
The selection of an only treatment or combination depends principally on the location of the
tumour, its size, histological subtype, stage and the patient's general state of health. Surgery
and RTP tend to be used alone to treat cases of non-metastatic disease (stages I and II), whereas
more advanced cancers (III and IV) are treated by surgery in combination with radiotherapy
and/or chemotherapy. It is important to bear in mind that the surgeries these patients undergo
are aggressive. They provoke aesthetic and functional alterations that affect the patient’s
quality of life.
Prior to undergoing radiotherapy treatment, it is important that patients with head and neck
cancer undergo a dental evaluation. This is because surgery provokes big aesthetic and
functional alterations. Therefore, patients who already show deficient oral health before
treatment are likely to leave their oral hygiene, increasing the gravity of complications.
There are a number of complications that appear in the head and neck region, not only during
treatment but also, after. These include mucositis, dental caries and xerostomia. In this paper,
we will describe the adverse, acute and late complications, as well as the treatment guidelines.
Furthermore, we will develop a patient management protocol for before, during and after
radiotherapy.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and eproduction in any medium, provided the original work is properly cited.
2. Head and neck cancer
The term oral cancer is used as a synonym for oral squamous cell carcinoma (OSCC), which
accounts for 90% of all head and neck cancers and 3-4% of malignancies [1, 2]. The incidence
of head and neck cancer has increased significantly over the past 20 years. Over 575,000 new
oral cancer cases are annually diagnosed in the world [3]. According to data published in 1998
by Spanish National Epidemiology Centre, in our country, the number of deaths by oral,
pharyngeal and labial cancer amounted to 1,891 of men and 374 of women. In Spain, incidence
accounts for 12 to 15 cases per 100,000 men/year and two to four cases per 100,000 women/
year [4]. However, the figures are now matching up. This is because some women are adopting
harmful habits, which were traditionally attributable to men. The disease mainly affects men
over 40 years of age, with a peak of maximum incidence in their 60s [5, 6].
The etiology of cancer has multiple factors. The main risk factors are smoking and alcohol.
Despite showing synergistic effects, these are independent risk factors, as shown in a study by
Castellsagué et al. [6, 7]. In some cases of solar ultraviolet radiation in lip cancer, infections,
diets low in fruit and vegetables, immunodepression, bad oral hygiene and the presence of
genetic factors can have a relevant effect.
Patients diagnosed with this cancer are treated by surgery, radiotherapy (RTP), chemotherapy
(QTP) or a combined treatment. The choice of a unique or combined treatment depends on the
location of the tumour, its extension, histological subtype, tumour stage and the patient's
general condition. Surgery and RTP are used in isolation to treat cases of non-metastatic disease
(stages I and II). However, advanced stages (III and IV) require concomitant RTP and QTP. In
the early stages, the treatment of choice is surgery. With this, the tumour is eliminated with
safety margins. This is achieved with or without cervical emptying, depending on the location,
size or suspicion of regional metastasis. Once the cervical emptying is completed and analysed,
if the structures are affected, subsequent treatment with RTP is evaluated. Advanced stages
can be treated with surgery followed by RTP but this combination only cures a minority of
patients and fewer than 30% will be alive at five years. With these treatments, tumour control
and survival rates are unsatisfactory. Only 30% of patients will be alive after three years, while
60-70% of patients will have a loco-regional recurrence and/or will develop distant metastasis,
which, ultimately, is the main cause of death in these patients [8].
QTP, in addition to RTP and surgery, is associated with a better general survival rate in patients
with oral or oropharyngeal cancer. Induction QTP can extend survival from 8% to 20% and
concomitant adjuvant chemo-radiotherapy can prolong survival up to 16%.
QTP consists of the administration of cytotoxic drugs that are capable of destroying and
inhibiting the growth and reproduction of malignant cells [9]. In head and neck cancers, the
most extensively used drugs are bleomycin, cisplatin, methotrexate, 5-fluorouracil, vinblastine
and cyclophosphamide [10]. QTP can be developed by administering one or more chemother‐
apeutic drugs. The use of isolated drugs (mono-chemotherapy) has proven useless in the
induction of significant complete or partial responses. Thus, the current trend is polychemo‐
therapy, which affects the cellular populations in different cell-cycle phases. This is achieved
by using the synergistic action of the drugs, decreasing the development of resistance to them
and promoting a higher response per administered dose [10]. The most used combinations
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include cisplatin and 5-fluorouracil; cisplatin, 5-fluorouracil and taxol or cisplatin, bleomycin
and methotrexate. Cytostatic drugs offer better results in tumours with a significant growth
fraction and/or early distant or frequent dissemination such as lymphomas (90% growth
fraction). This is not the case for squamous cell carcinoma, which is the most common head
and neck malignancy (25% growth fraction). Therefore, QTP is usually associated with another
therapeutic modality [11].
RTP can be applied locally (brachytherapy) or externally (teletherapy). The external radio‐
therapy is the classic way to administer radiotherapy with a remote radiation source of the
organism. Sources of external irradiation are low voltage (X-ray), supervoltage (cobalt 60),
megavoltage (linear accelerator) and electron beam (power source). Of these, the most widely
used treatments for head and neck therapy are cobalt-60 and the linear particle accelerator [12].
External radiotherapy requires a division of the dose and a longer period to carry it out,
consisting of a weekly dose of 10 Gy, 2 Gy daily for five days and two days of rest, usually
spread out over a period of 5-7 weeks. Fractioned RTP allows a full high dose in the tumour,
respecting the normal adjacent tissue and decreasing toxicity. It also conditions the response
in healthy and tumour tissues by repairing injuries. This is because, compared to tumour tissue,
normal tissue repairs damaged DNA better, especially at low doses. It also promotes the
reoxygenation of tumour cells, increasing their radiosensitivity and the repopulation of the
tissue between fractions. This is particularly the case during weekends when the area is not
irradiated, thereby reducing the early effects [13]. The radiation dose depends on the location
and type of tumour and whether the RTP is used alone or combined with other treatment
modalities. When the RTP is exclusive, the dose is usually between 60 Gy and 80 Gy, whereas
the dose administered post-surgically is 50-60 Gy [1].
On the other hand, brachytherapy is a method that uses ionizing radiation. It places radioactive
material in the proximity of or within the tumour. There are different modalities of brachy‐
therapy, of which interstitial RTP is the most frequently used for head and neck tumours. In
this modality, Iridium 192 (Ir192) and Iodine 125 (I125) are the most frequent radioactive
sources.
RTP and QTP are combined to improve therapeutic results, increasing loco-regional tumour
control and distant metastasis [14].
There are different ways to classify the effects produced by RTP on head and neck regions, as
are shown in Table 1,2, 3 [10, 15-17].
EFFECTS ACUTE LATE
Mucositis Necrosis of soft tissue
Radiodermatitis Trismus
Opportunist infections Osteoradionecrosis (ORN)
Xerostomia Post-radiation caries
Alteration in taste
Table 1. Acute and late effects of RTP.
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CHRONOLOGY IMMEDIATE MEDIUM TERM LONG TERM
Mucositis Post-radiation caries Osteoradionecrosis
Alteration in taste Opportunist infections Tooth disorder
Xerostomia Necrosis of soft tissue
Radiodermatitis Trismus
Table 2. Chronology of RTP: immediate, medium term and long term effects.
EVOLUTION REVERSIBLE IRREVERSIBLE
Mucositis Xerostomia
Radiodermatitis Alteration in taste
Xerostomia Post-radiation caries
Alteration in taste Osteoradionecrosis
Opportunist infections Tooth disorder
Necrosis of soft tissue
Trismus
Table 3. Evolution of RTP: reversible and irreversible effects.
2.1. Acute complications of radiotherapy
a. Mucositis is the inflammation of the oral-oropharynx as a result of the cytotoxic effects of
RTP. It is the most common complication that appears among patients who have been
irradiated with neck and head cancer, with an incidence of 80 %. Mucositis is dose-
dependent and therefore, it disappears with the end of the aggression [18]. The risk and
its gravity depend on the characteristics of the treatment such as doses, size of the
irradiated zone and its division.
The first sign is erythema, which appears when a dose of 10 Gy is accumulated (first week)
and persists up to 15 days after the end of the RTP treatment. The point of maximum symp‐
tomatology is when there are accumulated doses of 60-70 Gy [19, 20]. Clinically, the mucosa
is erythematous and edematous so it can become ulcerated and infected by fungi [19, 21]. The
pain that accompanies mucositis can be so intense that it alters the patient's quality of life,
limiting their basic oral functions such as speaking, swallowing saliva or eating [21].
Mucositis can be classified in four degrees, according to the intensity of the mucosa [16, 22]:
Grade 0: None (Figure 1).
Grade 1: Erythaema (Figure 2 and 3).
Grade 2: Erythaema, ulcers but capable of ingesting solids (Figure 4).
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Grade 3: Ulcers, requiring liquid diet (Figure 5).
Grade 4: Oral feeding is impossible (Figure 6).
Figure 1. Grade 0.
Figure 2. Grade 1.
Figure 3. Grade 1.
Figure 4. Grade 2.
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Figure 5. Grade 3.
Figure 6. Grade 4.
b. RTP facilitates the surge of opportunist infections, mainly Candida (Figure 7 and 8) as a
result of the reduction of saliva, the use of dentures, deficient oral hygiene and the
persistence of habits such as smoking or drinking [23]. These types of infections tend to
disappear with topical anti-fungal drugs. However, irradiated patients frequently have
to use more effective systemic drugs [24].
Figure 7. Candidiasis during RTP.
Figure 8. Candidiasis during RTP.
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c. Radiodermatitis is considered as skin and subcutaneous tissue toxicity. Depending on its
severity, it is classified in three different levels. Transitory erythaema is produced by the
congestion of dermal papillae within the first 24 hours. A dose of 3 Gy is enough to trigger
it (Figure 9 and 10). A dose of 25 Gy will produce an acceleration of the skin flaking process,
which is manifested as a significant decrease of thickness. This will then become dark,
atrophic and flaky, which is called dry radiodermatitis (Figure 11). A 50-70 Gy dose will
cause a delayed erythaema, followed by a superficial necrobiosis and the formation of
skin scabs. If these lesions progress, bleeding vesicula easily appears, which is called wet
radiodermatitis (Figure 12). These lesions are cured when the RTP treatment has ended,
leaving scars on the skin. These can be white and esclerotic telangiectastic. Follicles are
destroyed and, on occasions, pigmentations can appear [10].
Figure 9. Radiodermatitis: Grade 0, 5 sessions of RTP.
Figure 10. Radiodermatitis Grade I, 10 sessions of RTP.
Figure 11. Radiodermatitis: Grade II, 17 sessions of RTP.
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Figure 12. Radiodermatitis Grade III, 24 sessions of RTP.
d. Most patients suffer xerostomia or salivary hypofunction due to RTP in head and neck
cancers. This usually appears within the first weeks of radiation. In low doses (under 30
Gy), it is believed that the damage can be reversible. However, higher doses (over 60-70
Gy) result in an irreversible and permanent xerostomia. With the latter, there is a signif‐
icant degeneration of the acini, which is reflected by concomitant inflammation and
fibrosis of the interstitium (Figure 13).
Figure 13. Rough tongue due to salivary hypofunction.
e. Salivary hypofunction (a resting saliva flow of less than 0.2 ml per minute or a stimulated
flow of less than 0.7 ml per minute) is caused by the damage of direct ionizing radiation
of the salivary glands’ cells [25]. This is the most persistent effect in patients submitted to
RTP for head and neck tumours. It is characterized by changes in the amount and quality
of saliva (more viscous and scarce). It produces oral discomfort and pain, a higher risk of
dental caries, oral infection, difficulty of speech and disfagia. This has a damaging effect
on the patient’s quality of life [26-28]. The reduction of salivary flow can also increase the
susceptibility of the dental caries and takes into account the integrity of the mucosa [29].
f. The alteration in taste is a result of direct radiation of the taste buds and receptors of taste,
as well as changes in the saliva [30-32]. It contributes to loss of appetite, which results in
the patient’s weight loss. It appears 15 days after the treatment starts from the 4 Gy and
it reaches its maximum once the RTP is finished. In most cases, the sense of taste gradually
returns to normal or almost normal levels one year after radiotherapy [33]. However, some
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patients can experience a residual reduction of taste (hypogeusia), permanent damage to
the sense (disgeusia) and the loss of taste (ageusia) [34, 35].
2.2. Late complications of radiotherapy
a. There is a necrosis of soft tissue characterized by an ulcer located in the irradiated tissue,
without the presence of residual malignancy (Figure 14 and 15). It is usually a painful
condition and the tissues present a pale colour and lack of flexibility [36].
Figure 14. Necrosis of soft tissue two months after finishing RTP.
Figure 15. Necrosis of soft tissue two months after finishing RTP.
b. Trismus is characterized by a reduction in the opening due to the contraction and even
fibrosis of the masticating muscles and the ATM (Figure 16). It appears between three and
six months after radiation [23]. It can result in eating and communication problems. It also
impacts oral hygiene and the use of prosthesis, as well as the development of dental
treatments.
Figure 16. Still suffering from trismus one and a half years after finishing the RTP.
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c. Osteoradionecrosis could be the most severe RTP complication [38]. It is defined as an
area of bone exposure in a previously irradiated area, of at least six weeks of evolution
and in absence of tumour recurrence [37]. ORN is the result of reduced vascularity of
periodontal bone, the periosteum. It causes hypovascular, hypocellular and hypoxic
tissue, where the capacity of bone repair and regeneration is severely compromised
[38-40]. It can be asymptomatic or it can produce pain, dysaesthesia or anesthesia,
depending on its relation with the dental nerve. Patients report halitosis, trismus and
dysgeusia. Patients find that ORN impacts food in the lesion and they have difficulties in
chewing and swallowing, as well as exhibiting phonation [36]. In most cases, the condition
is chronic, developing gradually and becoming wider and painful [38, 41].
There are risk factors that can bring about ORN. These can be related to the tumour, with the
patient and with the treatment. With regard to factors that depend on the patient, we funda‐
mentally focus on the realization of post radiotherapy extractions. In fact, the development of
ORN with no previous surgery has proved to be extremely strange (incidence of 2.7% after
five years). Some other determinant factors are poor oral hygienic, previous irradiations of the
zone and the presence of periodontitis. Further factors include bad habits such as tobacco and
alcohol. Depending on the treatment, the risk factors are the administrated dose, its division,
the RTP type and the irradiated zone. Ultimately, the risk factors, depending on the tumour,
include the anatomical localization, the proximity of other bone structures and the size of the
tumour. These factors must be taken into account because they increase the risk of ORN and
if we are aware of them, we can prevent it.
Most ORN cases take place in the jaw. Here, vascularization is deficient and there is high bone
density (Figure 17, 18 and 19). Clinical manifestations of ORN may include pain, orofacial
fistulas, exposure of the necrotic bone, pathological fractures and suppuration [42].
Figure 17. ORN in the jaw after extraction post-RTP.
Figure 18. ORN in the jaw after extraction post-RTP.
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Figure 19. ORN after four months of finishing the RTP. Extraction had been carried out pre-RTP.
One third of ORN cases are spontaneous, although most cases occur due to teeth removal
during radiotherapy or during an insufficient healing time after pre-RTP extractions. Accord‐
ing to Starcke, Shannon, Murray and Makkonen, when the pre-RTP tooth removal is performed
correctly and a certain period passes, a significant increase of osteorradionecrosis is not
observed [43-45].
Figure 20. Spontaneous ORN in the jaw after RTP.
Figure 21. ORN after extraction post-RTP.
Incidence of ORN is two times higher in patients with teeth, although poor dental hygiene and
continued drinking and smoking can also contribute to its quick appearance [46]. A higher
incidence of osteoradionecrosis has been observed after receiving doses of over 65 Gy. This
depends on the fractioning of radiation and the treatment with QTP or surgery in the irradiated
area [47] (Figure 22 and 23 - case report of ORN that, after seven months of treatment, positively
developed chlorhexidine.).
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Figure 22. ORN two months after finishing the RTP, without previous extractions.
Figure 23. After seven months of good oral hygiene and rinses with chlorhexidine and chlorhexidine gel, it has pro‐
gressed favourably.
d. Dental caries are very frequent in post-radiation starting three months after RTP has
ended. There is a collapse and detachment of the enamel prisms that mainly affect the
incisal edges, cuspids and cervical region of the teeth [10] (Figure 24). This is the result of
a quantitative and qualitative alteration in the saliva, with a decrease of its stopping
capacity. This favours the development of an acidogenic-cariogenic bacterial flora. A
change towards a soft carbohydrate-rich diet, poor dental hygiene and the deterioration
of motivation also influences this (Figure 25).
For irradiated patients, dietary changes - a softer or liquid diet with a higher concentration of
carbohydrates - combined with a decrease in saliva, results in a change in the microbiota. This
becomes increasingly cariogenic. This, in addition to poor dental hygiene, results in a demin‐
eralization of the enamel and the destruction of crowns and the cervical area. Here, the cement
and dentin is exposed to the oral environment, producing increased dental sensitivity [48].
Figure 24. Dental wear during RTP.
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Figure 25. Accumulation of plaque due to poor hygiene during RTP.
3. Protocol for management before RTP
In literature of this subject area, there are articles published on the management of complica‐
tions in patients with head and neck cancer. These mainly focus on mucositis, radiodermatitis
and osterradionecrosis. However, in order for this to be prevented, we must monitor the
patient before, during and after radiotherapy. In this chapter, therefore, we will focus on the
management of the radiated patient, mainly before radiotherapy. This is because there are few
protocols and we believe that these are necessary in order to minimize the risks during
treatment.
Figure 26 and 27: Orthopantomography of a patient before beginning the RTP and two years
after finishing the RTP.
Figure 26. Before RTP.
Figure 27. After RTP.
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3.1. First visit
During the first visit, we collect the clinical history including the patients’ personal data: age,
gender, family medical history, personal medical history, current medical problems, medica‐
tion, allergies and harmful habits. All patients are referred with an oncological report,
including their medical history: tumour diagnosis, tumour stage and tumour treatment. A
mouth X-ray is also included to evaluate the dental status. A bucodental exploration is
developed to assess the oral situation of the patient and evaluate different therapeutic needs,
covering the RTP protocol.
3.1.1. RTP protocol
1. All patients must bring orthopantomography and report your oncological data.
2. Medical history is covered.
3. On each visit, a radiographical series from the patient is necessary - extraoral (mouth
closed, neck and maximum opening of the mouth) and intraoral (maxima intercuspida‐
tion, lateral intercuspidation, top and lower arcades, buccal mucosa and tongue), as is
shown in Figures 28-38.
4. An exploration of the mucosa is developed (yugal mucosa, lips, tongue, gums, bottom of
the vestibule, floor of the mouth, palate, etc.), in order to discard any pre-existing lesion.
5. A dental and periodontal exploration is developed with the assistance of a probe and
mirror. The degree of dental hygiene is determined using the Silnesloe index [49].
Grade 0: Absence of dental plaque.
Grade 1: Plaque not visible but could be extracted from the gingival third of the tooth using
the probe.
Grade 2: Moderate build-up of plaque in the gingival region that could easily be seen.
Grade 3: Abundance of plaque in the same region, possibly covering the neighbouring teeth.
6. The maximum interincisal distance is measured with callipers (a trismus is a bucal
opening of less than 40 mm).
7. A culture is carried out. The sample is taken from the back of the tongue and the readings
are at 24-48-72 hours. The sample is taken from the back of the tongue using a cotton swab,
depositing it in an agar-sabourand plate and placing it in the furnace for 72 hours.
8. The status of the saliva function is assessed using a chart paper strip (1 cm thick by 17 cm
length, with 1 cm not charted), introduced in a polyethylene bag. This is called a Global
Saliva Test, in rest and stimulated [50]. The section of non-charted strip is extracted from
the bag for testing. The end is then folded in a right angle and inserted in the oral cavity,
below the tongue. When closing the lips, these will slightly touch the polyethylene bag.
The saliva produced is accumulated in the lingual vallecule during the five minutes of the
test’s duration. During this time, the strip slowly soaks. Once this time has ended, it is
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retrieved from the mouth and the wet charted strip is immediately read. Subsequently,
the stimulation test is carried out by depositing some drops of citric acid at 4% in the oral
cavity and repeating the same process.
Figures 28-39: Radiographical series from the patient going to treatment with RTP.
Figure 28. Mouth closed.
Figure 29. Neck.
Figure 30. Maximum opening of the mouth.
Figure 31. Maximum intercuspidation.
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Figure 32. Right lateral intercuspidation.
Figure 33. Left lateral intercuspidation.
Figure 34. Top arcade.
Figure 35. Lower arcade.
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Figure 36. Right buccal mucosa.
Figure 37. Left buccal mucosa.
Figure 38. Tongue.
9. Once the odontogram is covered, with the assistance of an ortopantomography, the
therapeutic needs will be defined:
• Extraction (if this is necessary, all patients will sign an informed consent explaining all
the possible complications).
• Seals/endodontics.
• Treatment for oral candidiasis (mycostatin - mouth wash three times a day for three
minutes for four weeks).
• Tartar removal, scaling and root planning.
• Remove irritants that graze (traumatic prosthesis and sharp teeth).
• Motivation in oral hygiene - strongly recommend a daily teeth brushing for at least
three times a day with toothpaste with high fluoride content. Apart from Fluoridation
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plan in patients with teeth - preparation of individual trays for the daily application of
sodium fluoride gel at 1.24%, five minutes/day, indefinitely and mouth wash with
chlorhexidine.
10. If extractions are recommended [51, 52], the prognosis of the tooth itself, the patient's
motivation and their ability to follow oral hygiene instructions plays a role. All teeth with
a questionable prognosis should be extracted before RTP:
• Caries (non-restorable).
• Active periodontal disease (symptomatic teeth).
• Moderate and severe periodontal disease (≥ 5 mm bags) especially with advanced bone
loss, mobility and furcation involvement.
• Partial impaction or incomplete eruption, especially of third molars, which are not fully
covered by the alveolar bone or in contact with the oral cavity.
• Extensive periapical lesions (if not chronic or well localized).
• Root fragments that are not completely covered by alveolar bone or show radiolucency.
• Teeth near the tumour or in the tumour.
• Lack of opposing teeth.
• Compromised hygiene.
When developing extractions, patients should be handled as follows [52-54].
• Antibiotic prophylaxis for patients who need it, as recommended by the ADA.
• Rinse with antiseptic mouthwash - chlorhexidine digluconate 0.12% for one minute.
• Anaesthetic technique:
• Anaesthesia with vasoconstrictor.
• Minimal trauma - regularization of the alveolar process by approximation of edges.
• Non-absorbable 4.0 silk suture.
• Antibiotics, Amoxicillin 750 mg 1/8 hours /7 days is prescribed.
• Post-operative treatment: analgesic-anti-inflammatory medication (ibuprofen 600 mg) and
antiseptic mouthwash, chlorhexidine digluconate 0.12%.
• Minimum number of sessions, starting with mandibular extractions.
Most authors agree that the minimum delay time for RTP treatment is 15-20 days [39, 44, 52,
55]. While others indicate that, in the case of complex surgical procedures, patients must wait
four to six weeks [10, 54].
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Management before RTP
1. Report your oncological data.
2. Clinical history and bucodental exploration.
3. Orthopantomography.
4. Bucodental exploration.
5. The therapeutic needs will be defined: seals, endodontics and extractions.
6. Instructions and motivation in oral hygiene.
7. Global Saliva Test, in rest and stimulated.
8. Maximum interincisal distance.
9. Culture and identification of candidiasis.
4. Protocol for management during RTP
Patients who are to receive radiation therapy experience three main acute complications that
cause functional disability and hinder the development of normal life. These are mucositis,
radiodermitis and xerostomia. Weekly monitoring is required, i.e., we must see the patient
once a week during the eight weeks that the treatment usually lasts. The main symptoms
appear after the fifth dose of radiation. Thus, on each visit, we usually develop the following
measurements covered in the protocol.
4.1. RTP protocol
a. Degree of mucositis.
b. Degree of radiodermatitis.
c. Degree of oral hygiene - Silnesloe index [49].
d. Presence of ORN.
e. Eliminate possible graze, if the patient has removable/complete prosthesis.
f. Dental state and instructions in oral hygiene.
g. Saliva amount by means of TSG I and TSG II [50].
h. Culture at mid-treatment and at the end.
i. Maximum interincisal distance at mid-treatment and at the end.
j. Radiographical series from the patient is necessary - extraoral (mouth closed, neck and
maximum opening of the mouth) and intraoral (maxima intercuspidation, lateral inter‐
cuspidation, top and lower arcades, buccal mucosa and tongue).
k. Motivation in oral hygienic, strongly recommend a daily teeth brushing for at least three
times a day with toothpaste with high fluoride content. Apart from Fluoridation plan in
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patients with teeth - preparation of individual trays for the daily application of sodium
fluoride gel at 1.24%, five minutes/day, indefinitely and mouth wash with clorhexidine
During the radiotherapy treatment - and even 18 months later - no surgery technique should
be used with these patients and if an endodontic treatment is necessary, dental apex cannot
be surpassed. We advise exercises and jaw movements in order to prevent trismus and, in this
way, the maximum opening can be kept.
We must insist on instructions on oral hygienic to prevent rampant caries. As these patients
suffer from intense pain in the oral cavity, we can advise a soft brush so as not to irritate the
mucosa, accompanied by a soft diet and anticariogenic.
Fundamentally, these patients report dryness of the mouth and less saliva. The quality of saliva
changes - it feels thicker which causes rampant caries. That, added to the functional disability
produced by mucosistis, leads patients to abandon oral hygiene. As a result, their dental status
worsens. Therefore, our treatment is based on prescribing oral rinses and insisting on the
acquisition of oral hygiene habits. Basically, the purpose of it is to relieve symptoms using a
formula. This includes using lidocaine hydrochloride 1% and chlorhexidine digluconate 0.12%
before meals to help reduce swallowing pain [56-61].
Patients must drink at least half a litre of water a day to get a good hydration. There is a
possibility of cryotherapy, above all in mucositis and occasioned by quimotherapics. There‐
fore, patients must thaw ice in their mouths every 30 minutes [62, 63].
Nowadays, there are saliva substitutes (sprays or gels that temporarily wet the oral mucosa -
these are palliative) and stimulants (lemon drops, chewing gum with xylitol and sialogogues,
among which the pilocarpine is the most important). Pilocarpine is an on-selective cholinergic
agonist, which stimulates the salivary secretion. However, in our protocol, it is not recom‐
mended due to its various side effects [64, 65]. We recommend drinking water to hydrate, diet
tips and good oral hygiene
As saliva decreases, the sense of taste disappears. Thus, a zinc element can be useful for the
restoration of protein responsible for the regulation of pores in taste buds. It is also important
to drink an abundance of liquids with meals and to slowly chew. This will liberate flavours
and stimulate saliva [32, 66].
As for mucositis, large ulcerations appear in the mucosa of the oropharynx and oral cavity.
Curing this disease usually takes three weeks. However, up to two months may pass before
they start to subside [15, 56-58, 67]. In terms of management, we must differentiate pain control
[68] and functional disability [60, 62, 69] by combining oral solutions (lidocaine hydrochloride
1% and chlorhexidine digluconate 0.12%) and a liquid or soft diet.
The election of treatment in the first phase of ulceration is to prevent infection. This can be
achieved through good oral hygiene and antimicrobial agents, such as clorhexidine mouth‐
wash, povidone iodine and hyaluronic acid gels, which form a film that restructures the
epitelio. With these measures, the bacteria colonization in injuries with ulcerous mucositis is
prevented but its apparition is not [70].
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As previously stated, these patients experience a lot of pain and so it is necessary to use anti-
inflammatories. These include Benzydamine, which is used as a mouthwash and reduces
concentrations of tumour necrosis factors. This is efficient in the reduction of intensity and the
lasting of injuries in the mucosa [71].
There are cytoprotective agents that eliminate free radicals acting as antioxidants. In this group,
we have amifostine, prostaglandins and sucralfalte. The amifostine is a protector against the
xerostomia during the radiotherapy treatment. It reduces its gravity and duration. However,
it has multiple adverse effects and so its use is limited [72, 73]. Sucralfate adheres to the walls
of the ulcer and constitutes a superficial barrier in the gastrointestinal tract. As a result, the
oropharingeo pain is reduced but mucositis is not prevented. Sucralfate has some antibacterial
activity so it aids the healing of injuries and stimulates the synthesis of the prostaglandins
[74-77].
It is difficult to specify which treatment should be elected as each patient responds differently
to radiotherapy. Our experience is that chlorexidine and hyaluronic acid [78] do no aid
aggressive injuries. Thus, in different cases of mucositis III and IV, we recommend the use of,
topic corticoids, mainly 0.5% Triamcinolone Acetonid, three times a day for three weeks. We
also recommend oral rinses or creams, depending on whether the injuries are unique or
multiple. The injuries develop favourably but as it is a corticoid, we have to suspend it
gradually [79, 80]. Keefe et al. affirm that the high-level mucositis pain can be relieved with
potent analgesic such as opiaceous [81].
Furthermore, we reviewed written studies on this subject and found that there are currently
no published articles referring to the association between the administration of cortisone and
the presence of recurrences in the head and neck. Moreover, if there are references in other
locations, such as the prostate or the skin, it remains the treatment of choice [82-84].
Nowadays, there are new therapies (biological response modifiers) conducted in the investi‐
gation phase. These eliminate the mucositis, mainly reducing the minimum development of
the mucositis and, specifically, various growth factors. They also contribute to the biological
process of mucosity destruction [85]. In this group, we mention palifermine keratinocyte
growth factor. In advanced degree cases, this sees reduced mucositis but has secondary effects
and thus, its use is restricted [86-88].
Low-energy laser therapy is an effective method for the prevention and management of
mucositis. It is used to accelerate the regeneration of tissues and stop swelling and pain [89-92].
It is also important to get a basic medium so that there is no mycosis. Thus, as a preventative
measure, we recommend bicarbonate water rinses before meals (dilute a spoonful of bicar‐
bonate in 200 ml of water). Additionally, in the case of candidiasis, the treatment of choice is
Nystatin (topical antifungal). Here, we suggest rinsing three times a day, for three minutes
over a period of four weeks. Optimal oral hygiene is crucial in order to reduce the risk of oral
mucositis [89]. In cases that do not respond to the topical treatment or severe infections, we
recommend systemic antifungal such as fluconazole, 150 mg. - daily doses for two weeks [93].
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Little can be done to improve the toxicity of the skin, aside from moisturizing several times a
day and not covering the area so it does not keep moisture. We also recommend leaving it to
air dry.
Patients usually experience weight loss due to difficulties in swallowing caused by mucositis.
Taste alterciones causes a loss of appetite and dietary recommendations are necessary.
Management During RTP
1. Revisions, once a week, during treatment with radiotherapy valued:
a) Degree of mucositis.
b) Degree of radiodermatitis.
c) Degree of oral hygiene.
d) Presence of ORN.
e) Eliminate possible graze, if the patient has removable/complete prosthesis.
f) Dental state and instructions in oral hygiene.
g) Saliva amount by means of TSG I and TSG II.
h) Culture at mid-treatment and at the end.
i) Maximum interincisal distance at mid-treatment and at the end.
2. Treatment of complications.
3. Instructions of oral hygiene.
4. Liquid or soft diet.
5. Avoid extractions.
6. Remove toxic habits.
7. Remove any mechanical trauma to the oral mucosa.
8. Exercise to reduce trismus.
5. Protocol for management After RTP
Patients are monitored one month after finishing RTP treatment, as well as at three months,
six months, nine months, 12 months and 18 months. From then onwards, patients are reviewed
semi-annually. A new OPG requested 12 months after ending RTP.
In each of the reviews, the oral condition of the patient is assessed to establish treatment needs,
developing the following examinations that are covered in the protocol.
5.1. RTP protocol
1. Odontogram with the current situation after undergoing RTP, dental and periodontal
status.
2. Rating of oral hygiene: the Silnesloe index [49]
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Grade 0: Absence of dental plaque.
Grade 1: Plaque not visible but can be extracted from the gingival third of the tooth using the
probe.
Grade 2: Moderate build-up of plaque in the gingival region that can easily be seen.
Grade 3: Abundance of plaque in the same region, possibly covering the neighbouring teeth.
3. Maximum interincisal distance is measured with a calliper (trismus is a mouth opening
of <40mm). Different exercises, which should be carried out in order to increase the oral
opening, are explained to the patient.
4. The state of the salivary function is quantitatively assessed by a Global Saliva Test (TSG),
both at rest (TSG I) and stimulated (TSG II), following the technique described by López-
Jornet et al. [50].
5. A culture of the lingual dorsum is developed for isolation and identification of the candida
species. The clinical form of candidiasis (subclinical, erythaematous, pseudomembra‐
nous) is assessed.
6. Mucositis and residual radiodermatitis are evaluated.
7. Avoid complete or removable prosthesis until six months post RTP. Weekly monitoring
is essential to prevent damages in the mucosa and always add soft filler.
8. An exhaustive inspection of the oral cavity to early diagnose the recurrences.
9. Radiographical series from the patient is necessary - extraoral (mouth closed, neck and
maximum opening of the mouth) and intraoral (maxima intercuspidation, lateral inter‐
cuspidation, top and lower arcades, buccal mucosa and tongue).
10. Motivation in oral hygienic - strongly recommend a daily teeth brushing for at least three
times a day with toothpaste with high fluoride content. Apart from Fluoridation plan in
patients with teeth - preparation of individual trays for the daily application of sodium
fluoride gel at 1.24%, five minutes/day, indefinitely and wash mouth with clorhexidine.
Patient attending the annual review after finishing the RTP. We see good oral and dental
hygiene and healthy appearance of mucous.
Follows the same pattern (mouth closed, neck, maximum opening of the mouth, maximum
intercuspidation, right and left lateral intercuspidation, top and lower arcade, right and left
buccaal mucosa and tongue).
Patient who comes to review after 14 months of finishing RTP. He has lost four lower
incisive and the root-canal therapy we sent to keep them up to remove them.
The first Figure 39 shows the patient's condition before the RTP. Siguentes figures show the
patient’s current state (mouth closed, neck, maximum opening of the mouth, maximum
intercuspidation, right and left lateral intercuspidation, top and lower arcade, right and left
buccaal mucosa and tongue).
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Figure 39. Before RTP
 
The figures below show the oral health status of different patients after one year of finishing
the RTP. Here, you can see the various statuses of rampant caries and poor oral hygiene,
except in a case where there is excellent oral hygiene
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5.2. Assessment of osteoradionecrosis
1. It is classified according to the grade of bone affectation [94, 95]. The time of apparition
after RTP and the association to exodoncias are valued either pre or post RTP.
Stage I: Osteoradionecrosis superficial - soft-tissue ulceration is minimal and only the exposed
cortical bone is necrotic.
Stage II: Osteoradionecrosis localized - the exposed cortical bone and underlying medullary
bone are necrotic.
IIA: Soft-tissue ulceration is minimal.
IIB: Soft-tissue necrosis (including orocutaneous fistulation).
Stage III: Osteoradionecrosis diffuse - bone necrosis full thickness of a segment (ability to
pathological fracture).
IIIA: Soft-tissue ulceration is minimal.
IIIB: Soft-tissue necrosis (including orocutaneous fistulation).
2. Diagnosis
It is based on the clinical findings and medical history of the patient with the confirmation of
a radiology study and biopsy - exposed area of bone necrosis due to tissue-irradiation,
minimum cure of three to six months, without evidence of local healing and neoplastic absence
enfermdad [38, 41, 96].
The symptoms can manifest months or years after the radiation of the patient. The injuries
appear as ulcerations, with the exposure of rough and necrotic bone. In some cases, the injuries
are discovered during a visual inspection of the cavity or due to the incommodity in a
determined part of the mouth.
3. Treatment
In the first stage, a conservative treatment must be carried out. First, all irritants of the mouth
are eliminated such as tobacco, alcohol and removable/complete prosthesis. Then, good oral
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hygiene and oral rinse with clorixidine 0,12 is carried out three times a day and a gel of
clorhexidine is applied on the injuries three or four times a day.
In stage II, there is symptomatology and so the previous actions must be completed with an
antibiotic treatment. In these cases, we can do a curettage of the exposed part until vital and
vascular zone [97].
In stage III, pain can be intense and fistulization, suppuration and fractures can occur. Here,
more radical surgery is needed to eliminate the osteolytic zone remaining vascularized [98].
5.3. Extraction post-RTP
The criteria established by Sulaiman et al. and Jansma et al. should be followed. After radiation
therapy, it is necessary to delay any surgery for 18 months in order to reduce risks. The
recommendations below should be followed [52, 53]:
• Rinse with antiseptic mouthwash - chlorhexidine digluconate 0.12%, one minute.
• Anaesthetic technique:
• -Anaesthesia without vasoconstrictor - truncal block, infiltrative anaesthesia, never intrali‐
gamental anaesthesia.
• Minimal trauma, alveolectomy, regularization of the alveolar process with no rotary
instruments.
• Primary sealing with mucoperiosteal flaps.
• Non-absorbable 4.0 silk suture.
• Always prophylactic antibiotic (Amoxicillin 750mg 1/8 hours/10 days, if allergic to penicil‐
lin, a combination of spiramycin and metronidazole (Rhodogil®) is prescribed - two every
eight hours, for 10 days).
• Post-operative treatment: analgesic-anti-inflammatory medication (Ibuprofen 600mg) and
antiseptic mouthwash chlorhexidine digluconate 0.12%, plus antibiotics.
• Space the extractions in time.
Management After RTP
1. Patients are monitored one month after finishing RTP treatment, as well as at three months, six months, nine
months, 12 months and 18 months. From then onwards, patients are reviewed semi-annually. A new OPG is requested
12 months after the end of the RTP.
a) Residual mucositis and radiodermatitis.
b) Grade of oral hygiene - oral hygiene motivation.
c) Presence of ORN.
d) Oral dental status.
e) Global Saliva Test (TSG), both at rest (TSG I) and stimulated (TSG II).
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Management After RTP
f) Culture.
g) Maximum interincisal distance.
2. Avoid extractions at least 18 months after finishing the RTP.
3. Avoid performing or complete/removable prosthesis for three to six months post-RTP.
4. Stimulate oral apertuta through exercises.
9. Treatment of Complications.
10. Diagnosis of recurrences.
6. Conclusions
Prior to initiating RTP treatment, all patients should be protocoled to ensure that they present
optimal oral conditions. In this way, local and systemic complications can be minimized during
and after treatment and measures that can be adopted to reduce adverse effects can be
established. We consider it vital to quantify resting and stimulated saliva production prior to
the commencement of RTP, as any previously existing xerostomia must be treated to prevent
complications during RTP. The utility of an oral assessment should be explained and the
importance of maintaining good oral health should be stressed.
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